MRC Centre for Transplantation
Lead Research Organisation:
King's College London
Department Name: Transplantation Immunology & Mucosal Bio
Abstract
Organ transplantation has saved the lives of many thousands of people, but transplants still don't last as long as they should. In addition, to prevent rejection, high doses of toxic drugs are used to dampen the immune response. These can not only harm the transplant, but can have lethal side effects on the recipient.
Since it started in October 2007, the Centre has made significant progress towards improving the health of people who need transplants. We have devised ways to make their transplanted organ survive longer. This includes the development of engineered proteins which, when planted in donor kidneys, reduce inflammation and blood clot formation after transplantation. In addition, we have pioneered less harmful, more natural methods to coax the immune system into accepting the transplant, using cells taken from the patient. Remarkably, as a result of monitoring the immune system, we are close to being able to judge which patients can stop taking conventional therapy without rejecting the graft. At the same time, we are developing advanced scanning techniques that will enable physicians to diagnose whether a transplant is inflamed and to offer appropriate treatment.
As we approach the next five years of development, we shall conduct clinical trials to establish whether these innovations can benefit healthcare as the basic research has promised. Potential benefits include extending the life of the transplant and offering transplantation to more of those in need. We are also supporting new branches of science that make success more likely.
Advances of this complexity are made possible by bringing together a large workforce of scientists, clinicians and technologists under the same roof. The MRC Centre for Transplantation has created this capability within the UK. It collaborates with the Centre for Medical Law and Ethics at King's College to ensure a high standard of communication and public engagement regarding the regulation and ethics of transplant research. A programme of special events and media coverage will help keep the public and patients informed during innovation. Health economists are also to be part of the Centre to provide the opportunity to make more accurate forecasts about the costs and potential benefits of our research.
Future success will depend on recruiting and training the brightest minds to deliver this work through the next 5-10 years of development and ensure the research is translated into social and economic benefit.
Since it started in October 2007, the Centre has made significant progress towards improving the health of people who need transplants. We have devised ways to make their transplanted organ survive longer. This includes the development of engineered proteins which, when planted in donor kidneys, reduce inflammation and blood clot formation after transplantation. In addition, we have pioneered less harmful, more natural methods to coax the immune system into accepting the transplant, using cells taken from the patient. Remarkably, as a result of monitoring the immune system, we are close to being able to judge which patients can stop taking conventional therapy without rejecting the graft. At the same time, we are developing advanced scanning techniques that will enable physicians to diagnose whether a transplant is inflamed and to offer appropriate treatment.
As we approach the next five years of development, we shall conduct clinical trials to establish whether these innovations can benefit healthcare as the basic research has promised. Potential benefits include extending the life of the transplant and offering transplantation to more of those in need. We are also supporting new branches of science that make success more likely.
Advances of this complexity are made possible by bringing together a large workforce of scientists, clinicians and technologists under the same roof. The MRC Centre for Transplantation has created this capability within the UK. It collaborates with the Centre for Medical Law and Ethics at King's College to ensure a high standard of communication and public engagement regarding the regulation and ethics of transplant research. A programme of special events and media coverage will help keep the public and patients informed during innovation. Health economists are also to be part of the Centre to provide the opportunity to make more accurate forecasts about the costs and potential benefits of our research.
Future success will depend on recruiting and training the brightest minds to deliver this work through the next 5-10 years of development and ensure the research is translated into social and economic benefit.
Technical Summary
In 2007, the Centre set out to convert its extensive knowledge of inflammation, immunity and tolerance into new treatment, diagnostic and prognostic technologies for the benefit of patients. Our priorities were to overcome the initial barriers to transplantation presented by the immune system and to induce tolerance in patients with guidance from immune prediction and monitoring, so reducing some of the major limitations of modern transplantation.
To do this, we created links with protein and cell therapeutics, imaging sciences and genetics, and between clinical specialities responsible for the treatment of patients with diabetes, liver, kidney, bone marrow and dental diseases. As a result, the first membrane-targeted therapeutic regulators are about to enter a multicentre efficacy trial; the cell therapy strategy has progressed to become part of several investigational protocols designed to induce tolerance; markers of tolerance are undergoing extensive evaluation in man; and new imaging ligands that detect activated complement fragments and migratory T cells have emerged. A teaching framework built around these goals is equipping trainees to engage in multidisciplinary research. A programme of patient and public involvement promotes awareness of the importance of science in transplant medicine and ensures we are responsive to their expectations.
Our plan is to regroup the expanded number of basic and clinical research programmes into fewer themes which reflect areas of strategic value. This includes islet and hepatocyte transplantation, where inadequate long-term outcomes are likely to benefit from the specific expertise of the Centre. In support, an expanded training scheme will develop leadership skills in the distinct areas defined by the new themes, i.e. protein and cell engineering, immune monitoring, imaging and informatics. A parallel theme to improve methods of health economic assessment for early research is designed to support these goals.
To do this, we created links with protein and cell therapeutics, imaging sciences and genetics, and between clinical specialities responsible for the treatment of patients with diabetes, liver, kidney, bone marrow and dental diseases. As a result, the first membrane-targeted therapeutic regulators are about to enter a multicentre efficacy trial; the cell therapy strategy has progressed to become part of several investigational protocols designed to induce tolerance; markers of tolerance are undergoing extensive evaluation in man; and new imaging ligands that detect activated complement fragments and migratory T cells have emerged. A teaching framework built around these goals is equipping trainees to engage in multidisciplinary research. A programme of patient and public involvement promotes awareness of the importance of science in transplant medicine and ensures we are responsive to their expectations.
Our plan is to regroup the expanded number of basic and clinical research programmes into fewer themes which reflect areas of strategic value. This includes islet and hepatocyte transplantation, where inadequate long-term outcomes are likely to benefit from the specific expertise of the Centre. In support, an expanded training scheme will develop leadership skills in the distinct areas defined by the new themes, i.e. protein and cell engineering, immune monitoring, imaging and informatics. A parallel theme to improve methods of health economic assessment for early research is designed to support these goals.
Planned Impact
Benefit to patients
Improved quality of life, graft and patient survival rates, fewer interventions including less use of drug and dialysis treatment:
- Painting the donor organ with protective treatment that reduces inflammation and increases the lifespan of the transplant
- Having to take fewer drugs with unpleasant or dangerous side effects achieved with regimens using cell therapies in place of conventional treatment with broad-acting drugs
- Better patient stratification with new biomarkers and immune monitoring, allowing reduced drug usage where immune tolerance has developed
- Shorter wait for a kidney transplant through more donor organs being available with the application of organ-painting
- Evidence should be visible within 5-10 years
Benefits to the NHS
Cost/resource/efficiency benefits gained through costs of treatment (drug and dialysis costs) and patient and graft outcomes:
- Lower dialysis costs by enabling more transplants to be carried out with the use of organ painting and by fewer patients having to return to dialysis after transplantation
- Lower cost of dialysis in the early post transplant period due to more rapid recovery of painted donor organs
- Lower maintenance drug costs by keeping patients on fewer drugs where immune tolerance can be detected and/or can be induced by cell therapy
- Increased patient and graft survival rates with wider application of these treatment and diagnostic technologies, within 10 years
Benefits to the Economy
Exploitation of IP to form new products which contribute to UK economy and allow return on public investment in the work of the MRC Centre/KCL, by:
- New intellectual property based around these therapeutic and biomarker technologies (interest already showing in new cytotopic products and biomarkers of tolerance)
- Healthcare savings since maintenance on a transplant is more cost-effective than dialysis.
Benefits to Wider Society
Engagement/participation, leading to:
- Public confidence in organ donation, building on our ability to engage the public and influence policy on matters that include research in transplantation
- Influence willingness to participate in organ donations schemes by appreciating the scientific commitment though research
Improved quality of life, graft and patient survival rates, fewer interventions including less use of drug and dialysis treatment:
- Painting the donor organ with protective treatment that reduces inflammation and increases the lifespan of the transplant
- Having to take fewer drugs with unpleasant or dangerous side effects achieved with regimens using cell therapies in place of conventional treatment with broad-acting drugs
- Better patient stratification with new biomarkers and immune monitoring, allowing reduced drug usage where immune tolerance has developed
- Shorter wait for a kidney transplant through more donor organs being available with the application of organ-painting
- Evidence should be visible within 5-10 years
Benefits to the NHS
Cost/resource/efficiency benefits gained through costs of treatment (drug and dialysis costs) and patient and graft outcomes:
- Lower dialysis costs by enabling more transplants to be carried out with the use of organ painting and by fewer patients having to return to dialysis after transplantation
- Lower cost of dialysis in the early post transplant period due to more rapid recovery of painted donor organs
- Lower maintenance drug costs by keeping patients on fewer drugs where immune tolerance can be detected and/or can be induced by cell therapy
- Increased patient and graft survival rates with wider application of these treatment and diagnostic technologies, within 10 years
Benefits to the Economy
Exploitation of IP to form new products which contribute to UK economy and allow return on public investment in the work of the MRC Centre/KCL, by:
- New intellectual property based around these therapeutic and biomarker technologies (interest already showing in new cytotopic products and biomarkers of tolerance)
- Healthcare savings since maintenance on a transplant is more cost-effective than dialysis.
Benefits to Wider Society
Engagement/participation, leading to:
- Public confidence in organ donation, building on our ability to engage the public and influence policy on matters that include research in transplantation
- Influence willingness to participate in organ donations schemes by appreciating the scientific commitment though research
Organisations
- King's College London, United Kingdom (Collaboration, Lead Research Organisation)
- University of Edinburgh, United Kingdom (Collaboration)
- Ingenza Ltd, United Kingdom (Collaboration)
- British Transplantation Society (BTS) (Collaboration)
- Newcastle University, United Kingdom (Collaboration)
- Chemocentryx (Collaboration)
- University of Hamburg, Germany (Collaboration)
- University of Cambridge (Collaboration)
- King's College Hospital Charitable Trust, United Kingdom (Collaboration)
- Stanford University, United States (Collaboration)
- Emory University, United States (Collaboration)
- University Hospital Coventry NHS Trust, United Kingdom (Collaboration)
- City of Guangzhou (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- University of Regensburg, Germany (Collaboration)
- Oxford University Hospitals NHS Trust, United Kingdom (Collaboration)
- Royal Liverpool and Broadgreen University Hospital NHS Trust (Collaboration)
- Washington University in St Louis, United States (Collaboration)
- Pure Protein LLC (Collaboration)
- Epsom and St Helier University Hospitals NHS Trust (Collaboration)
- Hannover Medical School, Germany (Collaboration)
- Manchester University NHS Foundation Trust, Manchester (Collaboration)
- Hull and East Yorkshire Hospitals NHS Trust (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- University of Leicester, United Kingdom (Collaboration)
- St James's University Hospital (Jimmy's) (Collaboration)
- Catholic University of Louvain, Belgium (Collaboration)
- University of Southampton, United Kingdom (Collaboration)
- Zhejiang University, China (Collaboration)
- University College London, United Kingdom (Collaboration)
- Nottingham University Hospital NHS Trust, Nottingham (Collaboration)
- Brussels Saint-Luc University Hospital (UCL) (Collaboration)
- August Pi i Sunyer Biomedical Research Institute (Collaboration)
- Vall d'Hebron University Hospital (Collaboration)
- Belfast Health and Social Care Trust, Belfast, United Kingdom (Collaboration)
- Institute for Clinical and Experimental Medicine (IKEM) (Collaboration)
- Cambridge University Hospitals NHS Foundation Trust, Cambridge (Collaboration)
- Academic Medical Center (Collaboration)
- Great Ormond Street Hospital (GOSH) (Collaboration)
- Royal Free London NHS Foundation Trust, United Kingdom (Collaboration)
- Nantes University Hospital - CHU Nantes (Collaboration)
- University of Hong Kong, Hong Kong (Collaboration)
- Charité Campus Virchow - Hospital (Collaboration)
- Milenia Biotec GmbH (Collaboration)
- University Libre Bruxelles (Université Libre de Bruxelles ULB) (Collaboration)
- University of Lubeck (Collaboration)
- Cardiff & Vale University Health Board, United Kingdom (Collaboration)
- Apellis Pharmaceutical (Collaboration)
- Royal Society of Edinburgh (RSE) (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Nantes University, France (Collaboration)
- Grants Admin Office (Collaboration)
- St George's Healthcare NHS Trust (Collaboration)
- Guy's and St Thomas' NHS Foundation Trust, London (Collaboration)
- University of San Francisco (Collaboration)
- Rigel Pharmaceuticals (Collaboration)
- Roslin Biocentre Ltd (Collaboration)
- Charité - University of Medicine Berlin (Collaboration)
- Queen Elizabeth Hospital Birmingham (Collaboration)
- Sheffield Teaching Hospitals NHS Foundation Trust (Collaboration)
- Queen Alexandra Hospital (Collaboration)
- Astellas Pharma (Collaboration)
- European Cooperation in Science and Technology (COST) (Collaboration)
- Opsona Therapeutics (Collaboration)
- University of Amsterdam (Collaboration)
- Harvard University (Collaboration)
- ALTA (Collaboration)
- British Association of Urological Surgeons (Collaboration)
- University of Pennsylvania, United States (Collaboration)
- European Commission, Belgium (Collaboration)
- University of Minnesota, United States (Collaboration)
- Royal London Hospital (Collaboration)
- University Hospital La Paz (Collaboration)
- Immune Tolerance Network (Collaboration)
- UCB Pharma, Belgium (Collaboration)
- University of Bristol, United Kingdom (Collaboration)
- NHS England, United Kingdom (Collaboration)
- Yeshiva University (Collaboration)
- Yale University (Collaboration)
- University of East Anglia, United Kingdom (Collaboration)
- Duke University, United States (Collaboration)
- Plymouth Hospitals NHS Trust, Plymouth (Collaboration)
- University of Colorado (Denver) (Collaboration)
- Genome Identification Diagnostics GmbH (Collaboration)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (Collaboration)
- University of Pittsburgh (Collaboration)
- Xian Jiaotong University, China (Collaboration)
- University of Mons, Belgium (Collaboration)
- Nagoya University, Japan (Collaboration)
- University Hospitals of Leicester NHS, United Kingdom (Collaboration)
- University Hospitals Birmingham NHS Foundation Trust, Birmingham (Collaboration)
- University of Bath, Bath (Collaboration)
- Royal Free Hospital (Collaboration)
- Cellogic GmbH (Collaboration)
- Portsmouth Hospitals NHS Trust (Collaboration)
- Imperial College Healthcare NHS Trust (Collaboration)
- University of Bern (Collaboration)
- University Hospitals of Leicester NHS Trust, Leicester (Collaboration)
- Cardiff University, United Kingdom (Collaboration)
- Novartis (Collaboration)
- NHS Health Scotland (Collaboration)
- Alexion Pharmaceuticals (Collaboration)
- Leeds Teaching Hospitals NHS Trust, United Kingdom (Collaboration)
- BMI The Beaumont Hospital (Collaboration)
- Beth Israel Deaconess Medical Center (Collaboration)
- Uppsala University (Collaboration)
- University of Warwick, United Kingdom (Collaboration)
- University of Oslo, Norway (Collaboration)
- Immunotech S.A.S. (Collaboration)
- Barts Health NHS Trust, London (Collaboration)
- University of Dresden (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Great North Children's Hospital (GNCH) (Collaboration)
- Medical Research Council (Collaboration)
- Salford Royal NHS Foundation Trust, Greater Manchester (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- University of Seville, Spain (Collaboration)
- Chelsea Therapeutics (Collaboration)
- Catalan Health Institute (ICS) (Collaboration)
- University Hospitals Leuven (Collaboration)
- TcLand Expression (Collaboration)
- University Hospital Regensburg (Collaboration)
- East Kent Hospitals University NHS Foundation Trust (Collaboration)
Publications
Sutcliffe RP
(2012)
Utility of drain fluid amylase measurement on the first postoperative day after pancreaticoduodenectomy.
in World journal of surgery
Cherian P
(2012)
Reply Letter to the Editors
in Liver Transplantation
Shi W
(2012)
A comprehensive cardiac motion estimation framework using both untagged and 3-D tagged MR images based on nonrigid registration.
in IEEE transactions on medical imaging
Delingette H
(2012)
Personalization of cardiac motion and contractility from images using variational data assimilation.
in IEEE transactions on bio-medical engineering
Khan SA
(2012)
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.
in Gut
Lapthanasupkul P
(2012)
Ring1a/b polycomb proteins regulate the mesenchymal stem cell niche in continuously growing incisors.
in Developmental biology
Koulmanda M
(2012)
Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival.
in Proceedings of the National Academy of Sciences of the United States of America
Hernandez DG
(2012)
Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain.
in Neurobiology of disease
| Title | 3D prostates |
| Description | 3D printed prostates |
| Type Of Art | Image |
| Year Produced | 2015 |
| Impact | Developed in collaboration with Nuada Medical for patient counselling and surgical planning during robotic procedures |
| Title | Translucent |
| Description | Tablet guided surgery |
| Type Of Art | Image |
| Year Produced | 2014 |
| Impact | Developed a tablet based tool and performed the first in man for surgical navigation in UK and Italy. Demonstrated at the World Robotic Surgery Event with KCL being the only selected University from UK amongst 12 globally |
| Description | Appointed expert member of clinical and ethics/legal sub-group, and author of report. Presentation of findings at the Royal College of Paedicatric Child Health and Department of Health |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | CORAL and subsequent Cochrane review on robotic cystectomy |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | - |
| Description | Citation in subsequent frameowrk document |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | Changed the arrangements for distribution for research purposes of organs retrieved but not transplanted |
| Description | Co-opted onto BTS council to represent Basic Science |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Elected member of BTS Clinical Trials Committee |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://bts.org.uk/chapters-committees/clinical-trials-committee/clinical-trials-committee-members/ |
| Description | Expert reviewer and collaborator |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Description | House of Lords Regenerative Medicine Report (3 Centre PIs gave independent evidence) |
| Geographic Reach | National |
| Policy Influence Type | Gave evidence to a government review |
| Description | Influence on TTS policy on China |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a advisory committee |
| Description | Invited to small working group at the Human Tissue Authority- in view of publications writtenon the subject and published in high impact factor ethics/law journals |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Guideline Title | . |
| Description | NICE guidance published in the BJUI |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | . |
| Description | Policy Document to guide clinical practice |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | Scientific Advisory Board, DIREKT EC Framework Programme |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in advisory committee |
| Description | Technology Strategy Board Assessor Briefing for Healthcare |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Description | The first international robotics training curriculum |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | - |
| Description | 6 x 4-year PhD studentships through Complement UK |
| Amount | £733,528 (GBP) |
| Organisation | Alexion Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Allergy, Immunology and Transplantation Research |
| Amount | $941,479 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 02/2016 |
| Description | Allergy, Immunology, and Transplantation Research |
| Amount | $25,920 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 07/2016 |
| Description | Capital Bid |
| Amount | £1,690,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 09/2015 |
| Description | Characterisation of glycan ligands recognised by collectin-11 in ischaemic kidney and development of a specific antagonistic probe |
| Amount | £907,007 (GBP) |
| Funding ID | MR/R010757/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Collectin-11 as a trigger of the innate immune response in renal transplantation |
| Amount | £560,440 (GBP) |
| Funding ID | MR/M012263/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 02/2018 |
| Description | Collectin-11 as a trigger of the innate immune response in renal transplantation |
| Amount | £560,440 (GBP) |
| Funding ID | MR/M012263/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Complement UK PhD studentships 2016 |
| Amount | £210,000 (GBP) |
| Organisation | Alexion Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 10/2016 |
| End | 09/2020 |
| Description | Design of Novel Immunotherapies for Prostate Cancer - from Bench to Bedside |
| Amount | £1,500,000 (GBP) |
| Organisation | Prostate Cancer Research Centre (PCRC) |
| Sector | Private |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 10/2019 |
| Description | Determining the role of coagulation proteases in the development of renal fibrosis |
| Amount | £316,572 (GBP) |
| Funding ID | MR/T000058/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2022 |
| Description | Developing the evidence base for an innovative anti-inflammatory/anti-fibrotic therapy |
| Amount | £79,468 (GBP) |
| Funding ID | MC_PC_18052 |
| Organisation | Kings Health Partners |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2020 |
| Description | Development of cytotopically modified antithrombotic agent for prevention of acute intra-graft thrombosis in transplantation |
| Amount | £1,829,783 (GBP) |
| Funding ID | 098300 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | EME programme award (Co-applicant with M Robson) |
| Amount | £1,168,806 (GBP) |
| Funding ID | 13/94/10 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2018 |
| Description | Efficacy and Mechanism Evaluation (EME) |
| Amount | £300,000 (GBP) |
| Funding ID | 13/94/55 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 02/2019 |
| Description | Efficacy and Mechanism Evaluation (EME) Programme |
| Amount | £1,241,563 (GBP) |
| Funding ID | 13/94/10 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 04/2019 |
| Description | Establishing the optimising Transplant Survival Clinic |
| Amount | £37,317 (GBP) |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Department | Guy’s and St Thomas’ Kidney Patients' Association (GSTT KPA) |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 09/2011 |
| End | 03/2014 |
| Description | Exploring the Links Between Regulatory T cell Populations and Development of HLA Antibodies in Renal Patients Awaiting Transplantation. |
| Amount | £274,253 (GBP) |
| Funding ID | MR/T006560/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 05/2023 |
| Description | Fan Qu visit - CSC fellowship |
| Amount | £20,000 (GBP) |
| Organisation | University of Leeds |
| Department | China Scholarship Council |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 10/2015 |
| Description | Funding for 4-year PhD studentships (x2) from KCL |
| Amount | £200,000 (GBP) |
| Funding ID | MJKRAAR |
| Organisation | King's College London |
| Department | School of Medicine KCL |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 09/2017 |
| Description | Immune Tolerance Network |
| Amount | $30,000 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 02/2017 |
| End | 01/2018 |
| Description | Immune Tolerance Network |
| Amount | $27,000,000 (USD) |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 02/2016 |
| Description | Impact Grant King's Policy Institute |
| Amount | £20,000 (GBP) |
| Funding ID | MJK9408 |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2013 |
| End | 12/2014 |
| Description | Intermediate Clinical Fellowship - Dr Nicholas Powell |
| Amount | £876,303 (GBP) |
| Funding ID | 101159/Z/13/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2018 |
| Description | Investigation into the efficacy of Mirococept in renal transplantation |
| Amount | £213,310 (GBP) |
| Funding ID | G1001197 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Investigator Driven Clinical Study Astellas |
| Amount | £76,000 (GBP) |
| Organisation | Astellas Pharma |
| Sector | Private |
| Country | Japan |
| Start | 10/2014 |
| End | 10/2015 |
| Description | KHP Challenge Fund |
| Amount | £73,882 (GBP) |
| Funding ID | R140807 |
| Organisation | King’s Health Partners |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2015 |
| Description | KHP R&D Challenge Fund |
| Amount | £96,708 (GBP) |
| Funding ID | R1405170 |
| Organisation | Guy’s & St Thomas’ Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2015 |
| Description | KHP Research Grant |
| Amount | £91,000 (GBP) |
| Organisation | King’s Health Partners |
| Department | King's Health Partners Research and Development Challenge Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2013 |
| End | 10/2014 |
| Description | KRUK Clinical Training Fellowship to Dr Philippa Dodd |
| Amount | £258,741 (GBP) |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | Kidney Research UK - M Robson |
| Amount | £199,867 (GBP) |
| Funding ID | RP1/2015 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 11/2018 |
| Description | Kidney Research UK Research Training Fellowship - Dr Philippa Dodd |
| Amount | £258,741 (GBP) |
| Funding ID | TF1/2014 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2017 |
| Description | King's Health Accelerator Award |
| Amount | £130,213 (GBP) |
| Organisation | King's College London |
| Department | King's Commercialisation Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2017 |
| Description | King's Together |
| Amount | £18,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2018 |
| Description | King's Worldwide Partnership Fund |
| Amount | £1,984 (GBP) |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 04/2016 |
| Description | MRC Centenary Award 2013 |
| Amount | £30,000 (GBP) |
| Funding ID | PO Number 4050246766 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 06/2013 |
| Description | MRC Centenary Award for early career researchers |
| Amount | £45,000 (GBP) |
| Funding ID | MR/J006742/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 12/2012 |
| Description | MRC Centre Directors Capital Bid 2013: CEL (Cell Engineering Laboratory) |
| Amount | £203,000 (GBP) |
| Funding ID | MR/J006742/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 03/2015 |
| Description | MRC Centre Grant. MRC Centre for Transplantation |
| Amount | £1,694,050 (GBP) |
| Funding ID | MR/J006742/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Centre for Transplantation Minor Equipment |
| Amount | £100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| End | 03/2018 |
| Description | MRC Clinical Training Fellowship for Dr Hannah Burton |
| Amount | £244,237 (GBP) |
| Funding ID | MR/M01813X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 08/2018 |
| Description | MRC Clinical Training Fellowship for Dr Hannah Wilkinson |
| Amount | £278,889 (GBP) |
| Funding ID | MR/P018513/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | MRC Clinical Training Fellowship for Dr Harriot Doiuthwaite |
| Amount | £223,234 (GBP) |
| Funding ID | MR/N020340/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 10/2019 |
| Description | MRC Clinical Training Research Fellowship for Dr Caroline Dudreuilh |
| Amount | £253,932 (GBP) |
| Funding ID | MR/S000852/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | MRC DPFS |
| Amount | £1,007,574 (GBP) |
| Funding ID | MR/N019334/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 05/2021 |
| Description | MRC Fellowship |
| Amount | £947,966 (GBP) |
| Funding ID | G0902288 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2010 |
| End | 09/2014 |
| Description | MRC Project Grant |
| Amount | £500,000 (GBP) |
| Funding ID | MR/M012263/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2018 |
| Description | MRC Research Grant |
| Amount | £2,482,245 (GBP) |
| Funding ID | G1001197 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC project Grant (Co-applicant with G. Lombardi) |
| Amount | £483,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2013 |
| End | 01/2016 |
| Description | Marato TV3 Foundation |
| Amount | € 324,500 (EUR) |
| Organisation | La Marató de TV3 Foundation |
| Sector | Charity/Non Profit |
| Country | Spain |
| Start | 10/2013 |
| End | 10/2016 |
| Description | MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis |
| Amount | £200,000 (GBP) |
| Funding ID | RP38/2014 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 11/2017 |
| Description | NIH research award |
| Amount | $308,873 (USD) |
| Funding ID | 5U01AI100807-03 |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 01/2015 |
| End | 06/2017 |
| Description | NIHR BRC Bridging Fellowship - Dr Niloufar Safinia |
| Amount | £66,989 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 09/2015 |
| Description | NIHR EME |
| Amount | £1,241,563 (GBP) |
| Funding ID | 13/94/10 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 05/2019 |
| Description | NIHR HS&DR (Health Services and Delivery Research) |
| Amount | £876,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 01/2020 |
| Description | National Institute of Health Research Efficacy and Mechanism Evaluation (EME) Programme |
| Amount | £1,677,143 (GBP) |
| Funding ID | 13/94/55 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 11/2020 |
| Description | Overcoming immunological barriers to regenerative medicine |
| Amount | £2,322,220 (GBP) |
| Funding ID | MR/L022699/1 |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Pilot funding for retinoid dietary intervention in ADPKD mice |
| Amount | £2,000 (GBP) |
| Funding ID | N/A |
| Organisation | PKD Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2013 |
| End | 06/2014 |
| Description | Project Grant Application - Targeting C5aR in chronic inflammation, renal fibrosis and late graft dysfunction |
| Amount | £464,744 (GBP) |
| Funding ID | MR/L020254/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2014 |
| End | 04/2017 |
| Description | Prolonging cardiac allograft survival by targeting the indirect antigen presentation pathway with an immunotoxin |
| Amount | £248,748 (GBP) |
| Funding ID | PG/17/52/33059 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2020 |
| Description | Prostate Cancer Research Centre King's College London |
| Amount | £1,500,000 (GBP) |
| Organisation | Prostate Cancer Research Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| Description | Quality in Organ Donation (QUOD) |
| Amount | £60,608 (GBP) |
| Funding ID | QUOD Centre |
| Organisation | NHS Blood and Transplant (NHSBT) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2016 |
| Description | ROTRF |
| Amount | £202,047 (GBP) |
| Organisation | Roche Organ Transplantation Research Foundation (ROTRF) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 10/2014 |
| End | 09/2016 |
| Description | Roche Organ Transplantation Research Foundation |
| Amount | £200,000 (GBP) |
| Funding ID | 560883191 ROTRF |
| Organisation | Roche Organ Transplantation Research Foundation (ROTRF) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 10/2014 |
| End | 09/2016 |
| Description | Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology |
| Amount | £237,939 (GBP) |
| Funding ID | MR/M022927/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology |
| Amount | £2,386,712 (GBP) |
| Funding ID | MR/M022927/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 06/2018 |
| Description | Targeting C5aR in chronic inflammation, renal fibrosis and late graft dysfunction |
| Amount | £571,620 (GBP) |
| Funding ID | MR/L020254/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | The Urology Foundation |
| Amount | £75,000 (GBP) |
| Organisation | Urology Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 01/2019 |
| Description | The role of Wnt signalling in prostate cancer |
| Amount | £306,654 (GBP) |
| Organisation | Prostate Cancer Research Centre (PCRC) |
| Sector | Private |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 04/2018 |
| Description | UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Lombardi) |
| Amount | £310,822 (GBP) |
| Funding ID | MR/L022699/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Steve Sacks) |
| Amount | £295,551 (GBP) |
| Funding ID | MR/L022699/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | UK-AIH |
| Amount | £10,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 12/2018 |
| Description | Wellcome Trust New Investigator Award (Dr Claudia Kemper) |
| Amount | £1,519,891 (GBP) |
| Funding ID | 102932/Z/13/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 03/2019 |
| Description | Wellcome Trust Principal Research Fellowship |
| Amount | £4,692,044 (GBP) |
| Funding ID | 091823/Z/10/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust Translation Award (Co-applicant with Richard Smith) |
| Amount | £1,300,000 (GBP) |
| Funding ID | 098300/Z/12/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2015 |
| Description | Wnt signalling in prostate cancer |
| Amount | £0 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 10/2020 |
| Title | An in vitro model for studying genes and functions regulated by endogenous RA/RAR |
| Description | Combining two inhibitors AGN193109, DEAB and a cell line mIMCD-3 cells, as well as other collecting duct cell lines, we have established an in vitro approach to defining endogenous RA/RAR activities, target mRNAs, microRNAs and other non-coding RNAs. This approach can be used for other similar studies, using the same cell line or different ones. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | We have published our work on mRNAs using this approach in PLOS One. We have again shown it worked perfectly on microRNAs, leading to a manuscript that will be published after ongoing validation. This can also lead to further grants. Other scientists can also be inspired to develop similar systems for studying functions of endogenous RA/RAR in other systems. |
| Title | Elispot Standardisation |
| Description | Measures number of cytokine-producing cells after stimulation in vitro |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Standarization of method that will be used to stratify kidney transplant recipients if the trial is positive |
| URL | http://www.biodrim.eu/description.html |
| Title | GAMBIT cell and mRNA collection |
| Description | cells mRNA from blood serum urine mRNA fresh urine |
| Type Of Material | Biological samples |
| Year Produced | 2009 |
| Provided To Others? | No |
| Impact | Future biomarkers of tolerance to be developed |
| Title | GFP-C3 mouse |
| Description | Mouse engineered to express fluorescein-labelled complement protein (C3) that can be tracked in vivo. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2013 |
| Provided To Others? | No |
| Impact | The mouse has only just been generated. |
| Title | Humanised mouse model |
| Description | Immunodeficient mice reconstituted with human blood to study human immune responses in vivo and develop strategies to interfere with them. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2011 |
| Provided To Others? | No |
| Impact | Publications and future collaborations. |
| Title | Immunotoxin to prolong graft survival |
| Description | An immunotoxin that kills donor passenger leukocytes can induce indefinite survial of donor allografts |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | This can be adopted in the clinic to prolong graft survival in humans. |
| Title | Indices of Tolerance Array |
| Description | Data on mRNA array |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Access by other researchers PMID: 21827613 |
| URL | http://GSO.htm |
| Title | KALIBRE mRNA and cell collection |
| Description | PBMC stored in liquid nitrogen mRNA from blood plasma fresh urine - frozen - mRNA extracted from urine |
| Type Of Material | Biological samples |
| Year Produced | 2012 |
| Provided To Others? | No |
| Impact | Not yet |
| Title | Kidney glycan array |
| Description | Release of glycans from ischaemic human kidney |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Potentially enables glycan array to identify biding ligands for collectin-11 |
| Title | Novel RARalpha agonists |
| Description | This will likely be a novel drug lead. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | RARalpha is the dominant isotype of RAR in both collecting ducts and podocyte cell lineages, where RAR signalling is found. Selectively activate RARalpha can avoid side effects of RARgamma (dry and itching skin) and RXR (potentially pro-fibrotic) and thus could become more selective renal therapy in AKI and CKD. |
| Title | Phospholipid Capture Enzyme Immunoassay (PCEIA) |
| Description | The PCEIA is a generic system for the assay of cytotopic agents (CTAs). CTAs are modified protein or peptides which possess the ability to bind to phosphatidyl serine (PS) and related acidic phospholipids in cell membranes. The assay uses PS deposited on the wells of microtitre plates as the capture step. The protein or peptide component of the CTA is then detected with a specific antibody followed by a secondary antibody linked to an enzyme component such as horseradish peroxidase. The signal is detected colorimetrically with an appropriate enzyme substrate. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | A PCEIA for the complement inhibitor Mirococept was initially developed in response to a regulatory requirement (from the UK MHRA) for an additional potency assay for this agent. It was reasoned that an assay which was dependent not only on the ability to bind PS but also on the antigenic identity of the CTA would be complementary to the existing biological assay for complement inhibitors which is cell-based. This proved to be the case and the new assay was incorporated into a revised MIrococept Investigational Medicinal Product Dossier (IMPD) filed in late 2013. We realized that the same capture step could be applied to all CTAs regardless of the modified "cargo". During 2014 we have validated this approach for the anticoagulant Thrombolexin and the complement terminal pathway inhibitor Cytectin. This work has been written up for publication and we expect it to contribute not only to the development of a range of CTAs but also to ultimate commercialization |
| Title | Ppbp null mice |
| Description | Ppbp null mice we re-derived at King's are proven fertile and develop normally, thus an excellent model for testing the roles for ppbp in a variety of disease models. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | This model is now being used to examine the roles for ppbp in late development of the urinary tract, platelet biology, endothelial-monocyte interaction, immunity, infection and kidney diseases. Once pilot data are appealing there will be new grant applications, etc. |
| Title | Rare-Luc mice |
| Description | This will allow quantitatively visualising RXR/RAR signalling at the whole animal, in tissues and at cellular levels. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | This will allow quantitatively visualising RXR/RAR signalling at the whole animal, in tissues and at cellular levels. |
| Title | Refinement of heart transplant technique |
| Description | A new less traumatic method to perform heart transplant in mice |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | It is now published, others using the technique can easily learn it with the help of an on line video |
| Title | TRE-dnRAR transgenic mice |
| Description | This line of mice will enable conditional expression of a dominant negative mutant of RAR to achieve conditional repression of RXR/RAR signalling in the mice. Once interred with Hoxb7-Tet On mice, we can then achieve conditional repression of RXR/RAR signalling selectively in the collecting ducts in adult mice. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | As RXR/RAR signalling is indispensable to kidney development, this line of transgenic mice will avoid renal abnormality induced by repression of RXR/RAR in embryonic mice and enable study of the roles for RXR/RAR signalling in both physiology and pathophysiology of adulthood. |
| Title | anti-human and mouse VISTA monoclonal antibidies |
| Description | antibodies specific to human and mouse VISTA |
| Type Of Material | Antibody |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | new target for immnotherapy |
| Title | laparoscopic renal transplantation |
| Description | an animal model for laparoscopic renal transplantation, a novel clinical technique, which has involved collaboration with Prof Campistol in Barcelona, and with the surgical department at St Georges hospital. The model is being refined with a view to translation to human subjects later this year. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | The model is being refined with a view to translation to human subjects later this year. |
| Title | 100,000 genome project for NHS England |
| Description | Contribution of kidney samples/data on 2,252 patients |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | none so far |
| Title | BAUS National database |
| Description | National outcomes of radical prostatectomy |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Publicly available data |
| URL | http://WWW.BAUS.ORG.UK |
| Title | British Association of Urological Surgeons, |
| Description | National Publicly available database |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | First such national data on cancer patients |
| URL | http://www.baus.org.uk/ |
| Title | Genome-wide database |
| Description | Genome-wide kidney transplant database from 28 UK and Ireland centres on 8,900 donor and recipient pairs (who also donated DNA). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Resource for further disease complications after transplantation. |
| Title | International Robotic Cystectomy Consortium |
| Description | Robotic cystectomy |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | . |
| Title | Liver Tolerance Database |
| Description | Database containing sequential liver histology from liver transplant recipients enrolled in immunosuppression withdrawal trials. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | - Identification of transient inflammatory changes in the liver allografts of patients undergoing successful immunosuppression withdrawal. - Has allowed us define the acceptable inclusion/exclusion criteria for future immunosuppression withdrawal trials. |
| Title | NHR-HIC |
| Description | Integration of anonymised clinical data and "omics" for research and clinical purposes |
| Type Of Material | Data handling & control |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | No impact yet. 4 collaborating groups: Cambridge, Oxford, Imperial and KCL. It will be expanded UK-wide within 3 - 5 years It will facilitate research and clinical practice in a large scale |
| URL | http://www.nihr.ac.uk/about/hic.htm |
| Title | NIHR-health informatics consortium in transplantation |
| Description | Part of the NIHR-HIC project for NHS England consisting of 6,300 samples |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | n/a |
| Title | Vattikui Collaborative Quality Initiative |
| Description | International outcomes of prostatectomy and partial nephrectomy |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | . |
| Description | Alexion Pharmaceuticals |
| Organisation | Alexion Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | We collaborated on an investigator led pre clinical study to determine the impact of complement inhibitor (anti-C5) on reperfusion injury in native and transplant kidneys. |
| Collaborator Contribution | Alexion Pharmaveuticals provided Chemicals, Consumables and animals to this study |
| Impact | The therapeutic antibody failed to penetrate into transplanted kidney and therefore helped to define types of injury that would not amenable to this particular therapeutic strategy. |
| Description | Anti inflammatory and anti thrombin - Duke University |
| Organisation | Duke University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | What the link embraces 1. Distinctive areas of strength that complement the academic plans at both Centres 2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills 3. Enhanced metrics for training in health services research 4. Benefits of cross-centre evaluation of clinical-academic programmes 5. Leveraging funding to support the proposed activities and goals |
| Collaborator Contribution | Research training and consumables including non human primates. |
| Impact | Abstract at the American Society for Transplantation |
| Start Year | 2015 |
| Description | Antibody Incompatible Transplantation |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Nizam Mamode set up and is Clinical Lead for the Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. As well as reporting outcome data, I am interested in the effect of B cell depletion on T cell responses in blood group incompatible transplant patients. This project was carried out at Guys but has involved collaboration with a national study of blood group incompatible patients (the ABOUT-K study run by Dr Simon Ball in Birmingham). |
| Collaborator Contribution | The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. |
| Impact | The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. |
| Start Year | 2012 |
| Description | Antibody Incompatible Transplantation |
| Organisation | University Hospitals Birmingham NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Nizam Mamode set up and is Clinical Lead for the Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. As well as reporting outcome data, I am interested in the effect of B cell depletion on T cell responses in blood group incompatible transplant patients. This project was carried out at Guys but has involved collaboration with a national study of blood group incompatible patients (the ABOUT-K study run by Dr Simon Ball in Birmingham). |
| Collaborator Contribution | The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. |
| Impact | The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. |
| Start Year | 2012 |
| Description | Apellis (Louisville, USA) |
| Organisation | Apellis Pharmaceutical |
| Country | United States |
| Sector | Private |
| PI Contribution | Experiments on the role of C5L2 in T cell responses in in vivo disease models. |
| Collaborator Contribution | Generation and provision of human C5L2 targeted reagents (agonists and antagonists). |
| Impact | Patent application pending |
| Start Year | 2012 |
| Description | Assessing the role of complement-mediated regulation of Th1 responses in health and disease |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We have discovered one of the molecular pathways controlling IFN-gamma ; 'shut down' in Th1 cells and the corresponding defect in RA patients T cells. We are now assessing this pathway in detail - as the 'basic science team' - and keep collaborating with the clinical team to asses if identified deregulation points can be predicted or corrected therapeutically in RA patients. |
| Collaborator Contribution | We have partnered with several clinicians working on rheumatoid arthritis (RA) at Guy's hospital. In addition, we are now included in an ongoing clinical trial at Guy's Hospital assessing factors that help predicting if and when RA patients can be 'weaned off' anti-TNF therapy. |
| Impact | "Grant money: 2011-2018. IMI (Innovative Medicine Initiative - FP7/2009) by the European Union. Understanding aberrant adaptive immunity mechanisms in human chronic immune-mediated diseases: rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. Application package jointly submitted by 14 European Research Institutions and 11 Biotechnology companies. Coordinating Director: Prof. Dr. T.W.J. Huizinga, Leiden University, Netherlands. €6.5 Mio. KingÂ' College portion: £680.000 Role: Leading Scientist (KingÂ's College Stream; Lead-PI: Andy Cope) 2011-2014 MRC Project Grant. The molecular and cellular basis of complement-mediated T helper 1 (Th1) differentiation and regulation. Kemper C, Cope A, Rebello-Mesa I and Lavender P. £860.000 Role: PI Peer reviewed publications: 1.Cardone, J, Le Friec, G, Vantourout, P, Roberts, A, Fuchs, A, Jackson, I, Suddason, T, Lord, G, Atkinson, JP, Cope, A, Hayday, A and Kemper, C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol 2010. 11(9):862-871. 2. Cope, A, Le Friec, G, Cardone, C and Kemper, C. The lifecycle of Th1 cells: molecular control of IFN-γ to IL-10 switching. TRENDS Immunol 2011. 32:278-286. 3. Cardone, C, Le Friec, G, and Kemper, C. CD46 in innate and adaptive immunity: An update. Clin Exp Immunol 2011. 164:301-311. 4. Heeger, P, and Kemper, C. Novel roles of complement in T effector cell regulation. Immunobiology. 2011. doi:10.1016/j.imbio.2011.06.004 Conference presentations/invited lectures: Immunology Seminar Series, Oxford University, Dunn School of Pathology; Complement and T cell homeostasis. 2010 Â'John Humphrey Seminar SeriesÂ' at Imperial College, London, UK; Complement: Tipping the balance between successful host defense and autoimmunity. 2010 Regional BSI group seminar series Cardiff University, UK; Complement during T cell activation: Timing (and the microenvironment) is key. 2010 BSI Annual Conference, Liverpool, UK; Complement, T cells and autoimmunity. 2011 Immunology Seminar Series, Cambridge University; Innate signals regulating Th1 immunity. 2011 Wright-Fleming Institute Seminar Series, Imperial College London; Towards a molecular Th1 life cycle signature. 2011 UCB, Slough, UK. Therapeutic interventions in Th1-mediated autoimmune disease states. 2011 8th International Conference on Innate Immunity, Chania, Greece: Innate immune signals in the regulation of Th1 responses. 2011 Annual BSI Â'Showcase of ImmunologyÂ', London, UK; CD46: Just a Notch up your common complement regulator." |
| Start Year | 2010 |
| Description | BIO-DRIM FP7 EU Consortium |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | We are the lead investigators in a multi-national clinical trial of immunosuppression discontinuation in liver transplantation. The trial involves clinical sites in UK, Germany, Belgium and Spain, and is funded in part by the EU FP7 BIO-DRIM Consortium. |
| Collaborator Contribution | Support on quality of life and health-economic analyses. Support on biomarker commercialisation strategy. |
| Impact | No outputs yet. |
| Start Year | 2013 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | ALTA |
| Department | Research and Development in Biotechnology |
| Country | Italy |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Astellas Pharma |
| Country | Japan |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Catalan Health Institute (ICS) |
| Department | University Hospital of Bellvitge (HUB) |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Cellogic GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Genome Identification Diagnostics GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Immunotech S.A.S. |
| Country | France |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Institute for Clinical and Experimental Medicine (IKEM) |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Milenia Biotec GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University Hospital of Nantes |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Amsterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Hamburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Regensburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | Brian Sutton- Crystal structure of VISTA |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We provide recombinant VISTA proteins for structural studies |
| Collaborator Contribution | They evaluate crystal structure of VISTA |
| Impact | None |
| Start Year | 2013 |
| Description | CL-11 Ligand characterization |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We established the relationship on the basis of preliminary data on Collectin-11. We provided the research question in support of the successful grant application awarded by the MRC. |
| Collaborator Contribution | Specialist knowledge concerning carbohydrate arrays enabling exploration of the Collectin-11 ligand on renal tissue. |
| Impact | preliminary carbohydrate array work carried out and being further developed. |
| Start Year | 2014 |
| Description | Cell therapy in liver transplant patients |
| Organisation | University of San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Comparison of cell therapy using two preparations of regulatory T cells in liver transplant patients with the same clinical therapy. |
| Collaborator Contribution | Generation of antigen-specific Tregs using B cells as antigen presenting cells. |
| Impact | 1 publication so far. |
| Start Year | 2011 |
| Description | Chelsea Therapeutics |
| Organisation | Chelsea Therapeutics |
| Country | United States |
| Sector | Private |
| PI Contribution | We have developed a biomarker for clinical trials. |
| Collaborator Contribution | The company provided a drug compound (an anti-folate) |
| Impact | We have published a paper, Pubmed ID: 18343249 |
| Start Year | 2007 |
| Description | Chemocentryx |
| Organisation | ChemoCentryx |
| Country | United States |
| Sector | Private |
| PI Contribution | Testing a human complement inhibitor (C5a receptor anatgonist) in animal models. |
| Collaborator Contribution | Donated the complement inhibitor and transgenic mice expressing the human target. |
| Impact | Grant submitted to the MRC using pilot data generated by this partnership. |
| Start Year | 2013 |
| Description | Collaboration with UCB |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Formal consultancy arrangement with UCB concerning planning and delivery of a phase 2 clinical trial in renal transplant patients |
| Collaborator Contribution | UCB will provide a novel drug for this investigator-led study |
| Impact | none yet |
| Start Year | 2016 |
| Description | Collectin 11 and lung inflammation with the University of Denver |
| Organisation | University of Colorado Denver |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Sent the breeding pairs of mice with deficiency of collectin 11 and telephone conference call set up. |
| Collaborator Contribution | Expertise on the animal model of lung disease |
| Impact | None so far |
| Start Year | 2016 |
| Description | Collectin 11 at the front line of tissue response stress - Complement UK research studentship |
| Organisation | Alexion Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | Prepared PhD project proposal and being the primary supervisor of the PhD student |
| Collaborator Contribution | Full PhD scholarship (4 years) |
| Impact | Obtained a full PhD studentship (4 years) |
| Start Year | 2013 |
| Description | Complement UK |
| Organisation | Cardiff University |
| Department | Infection and Immunity |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Great North Children's Hospital (GNCH) |
| Department | Pediatric Nephrology |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Imperial College London |
| Department | Faculty of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Department | Department of Clinical Haematology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Manchester University NHS Foundation Trust |
| Department | Nephrology and Transplantation |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Human Genetics Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Newcastle University |
| Department | Institute of Cellular Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | Newcastle University |
| Department | Institute of Human Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University College London |
| Department | Institute of Neurology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University College London |
| Department | Institute of Ophthalmology UCL |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University College London |
| Department | Research Department of Epidemiology and Public Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University College London |
| Department | Structural Molecular Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Bath |
| Department | Department of Biology and Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Bristol |
| Department | School of Cellular and Molecular Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Cambridge |
| Department | Department of Clinical Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of East Anglia |
| Department | School of Medicine UEA |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Edinburgh |
| Department | School of Biological Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Edinburgh |
| Department | School of Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Leicester |
| Department | Department of Infection, Immunity and Inflammation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Leicester |
| Department | Department of Molecular and Cell Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Oxford |
| Department | Sir William Dunn School of Pathology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Southampton |
| Department | School of Medicine Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement UK |
| Organisation | University of Warwick |
| Department | Warwick Medical School |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
| Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
| Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
| Start Year | 2009 |
| Description | Complement and Coagulation interaction in hyperacute rejection |
| Organisation | Imperial College London |
| Department | Faculty of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Rat model of hyperacute rejection. Model for therapeutic intervention by treatement of the donor organ with membrane associated thrombin and complement regulators |
| Collaborator Contribution | It has exposed new interactions between thrombin and complement regulators induced by antibody bidning and has identified a new therapeutic strategy for prevention of rejection |
| Impact | Presentation of findings at international complement and transplant meetings. Potential new treatment strategy relevant to sentised transplant recipients. New IP registered for the membrane targeted antithrombin (PTL004 and PTL006). |
| Start Year | 2008 |
| Description | Complement and Coagulation interaction in hyperacute rejection |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Rat model of hyperacute rejection. Model for therapeutic intervention by treatement of the donor organ with membrane associated thrombin and complement regulators |
| Collaborator Contribution | It has exposed new interactions between thrombin and complement regulators induced by antibody bidning and has identified a new therapeutic strategy for prevention of rejection |
| Impact | Presentation of findings at international complement and transplant meetings. Potential new treatment strategy relevant to sentised transplant recipients. New IP registered for the membrane targeted antithrombin (PTL004 and PTL006). |
| Start Year | 2008 |
| Description | Cost action BM1305. "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT)" |
| Organisation | European Cooperation in Science and Technology (COST) |
| Country | Belgium |
| Sector | Public |
| PI Contribution | ME and my team participate in 2 working subgroups "Flow Cytometry", "mRNA-QPCR analysis" and "Functional Analysis". Mainly in method harmonisation process |
| Collaborator Contribution | Provide talks, information, SOPs and collaborating in writing a manuscript |
| Impact | 1. Science Translational Medicine 09 Sep 2015: Vol. 7, Issue 304, pp. 304ps18 DOI: 10.1126/scitranslmed.aaa7721 2. 3 x Joint Management Committee (MC) and Working Groups (WG) Meetings have taken place in Newcastle (2014), Lisbon (2015) and Gdansk (2015) |
| Start Year | 2013 |
| Description | Cost action in preparation. "Immuno modulation strategies to improve outcomes in transplanted children" |
| Organisation | University Hospital La Paz |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Establishing objectives and partnership |
| Collaborator Contribution | n/a |
| Impact | n/a |
| Start Year | 2016 |
| Description | Cytectin structural studies |
| Organisation | University of Oxford |
| Department | Sir William Dunn School of Pathology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provided Cytectin |
| Collaborator Contribution | Oxford University provided data on its structural interaction with membranes. |
| Impact | Publication May 2013 Cell Reports Cell Rep. 2013 May 30;3(5):1369-77. doi: 10.1016/j.celrep.2013.04.029. Epub 2013 May 9. Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59. Johnson S, Brooks NJ, Smith RA, Lea SM, Bubeck D. PMID: 23665225 [PubMed - in process] PMCID: PMC3675674 |
| Start Year | 2013 |
| Description | Development of Cyclic Peptide libraries for discovery of novel prostate cancer therapeutics |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Developing single cell epigenetic analysis techniques of cyclic peptide epigenetic modification |
| Collaborator Contribution | Liam Fotheringham is developing the cyclic peptide libraries and Oscar Cez is developing fluidigm techniques for single cell epigentic information capture. |
| Impact | Innovate/BBSRC grant IBC4 application pending |
| Start Year | 2015 |
| Description | Development of Cyclic Peptide libraries for discovery of novel prostate cancer therapeutics |
| Organisation | Ingenza Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developing single cell epigenetic analysis techniques of cyclic peptide epigenetic modification |
| Collaborator Contribution | Liam Fotheringham is developing the cyclic peptide libraries and Oscar Cez is developing fluidigm techniques for single cell epigentic information capture. |
| Impact | Innovate/BBSRC grant IBC4 application pending |
| Start Year | 2015 |
| Description | Development of Cyclic Peptide libraries for discovery of novel prostate cancer therapeutics |
| Organisation | Roslin Biocentre Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Developing single cell epigenetic analysis techniques of cyclic peptide epigenetic modification |
| Collaborator Contribution | Liam Fotheringham is developing the cyclic peptide libraries and Oscar Cez is developing fluidigm techniques for single cell epigentic information capture. |
| Impact | Innovate/BBSRC grant IBC4 application pending |
| Start Year | 2015 |
| Description | EMPIRIKAL Consortium |
| Organisation | British Transplantation Society (BTS) |
| Department | Clinical Trials Network |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study. |
| Collaborator Contribution | Planning of the protocol. Potential patient involvement. |
| Impact | First investigator meeting held October 2012. Protocol modifications. |
| Start Year | 2012 |
| Description | EMPIRIKAL Consortium |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study. |
| Collaborator Contribution | Planning of the protocol. Potential patient involvement. |
| Impact | First investigator meeting held October 2012. Protocol modifications. |
| Start Year | 2012 |
| Description | EU Consortium |
| Organisation | University Hospital Regensburg |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Use of regulatory Tregs for the induction of tolerance in renal transplant patients |
| Collaborator Contribution | Use of different cell type with the aim to induce tolerance in renal transplant patients |
| Impact | Few manuscripts submitted. |
| Start Year | 2010 |
| Description | Emory |
| Organisation | Emory University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Clinical fellows exchange programme adding value to joint research projects between Emory and KCL. |
| Collaborator Contribution | What the link embraces 1. Distinctive areas of strength that complement the academic plans at both Centres 2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills 3. Enhanced metrics for training in health services research 4. Benefits of cross-centre evaluation of clinical-academic programmes 5. Leveraging funding to support the proposed activities and goals |
| Impact | Dr Stuart Hurst, a medical trainee from Emory, started the collaborative programme by joining the MRC Centre for Transplantation for 2 years in July 2013, under Professors Anthony Dorling and Steven Sacks' supervision. Dr Blayne Sayed from Emory has joined the MRC Centre in July 2014 under the supervision of Professor Alberto Sanchez Fueyo. The MRC Centre for Transplantation awarded MRC Centre two Emory Bridging Fellowships and appointed two female surgical trainees to carry out research projects at Emory in the USA. Their sabbaticals are due to start in 2015. |
| Start Year | 2013 |
| Description | FP7 Consortium |
| Organisation | ALTA |
| Country | Italy |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Astellas Pharma |
| Country | Japan |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Catalan Health Institute (ICS) |
| Department | University Hospital of Bellvitge (HUB) |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Cellogic GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Genome Identification Diagnostics GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Immunotech S.A.S. |
| Country | France |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Institute for Clinical and Experimental Medicine (IKEM) |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | Milenia Biotec GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | TcLand Expression |
| Country | France |
| Sector | Private |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University Hospital of Nantes |
| Country | France |
| Sector | Hospitals |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University of Hamburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | FP7 Consortium |
| Organisation | University of Regensburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics |
| Impact | FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance |
| Start Year | 2011 |
| Description | GAMBIT Consortium |
| Organisation | Cardiff and Vale University Health Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | East Kent Hospitals University NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Great Ormond Street Hospital (GOSH) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Hull and East Yorkshire Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Institute for Clinical and Experimental Medicine (IKEM) |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | King's College Hospital NHS Foundation Trust (NCH) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Manchester University NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Portsmouth Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Royal Free London NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Salford Royal NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | St George's Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | University Hospitals of Leicester NHS Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Uppsala University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT Consortium |
| Organisation | Vall d'Hebron University Hospital |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Cardiff and Vale University Health Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | East Kent Hospitals University NHS Foundation Trust |
| Department | Renal Services East Kent Hospitals University |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Great Ormond Street Hospital (GOSH) |
| Department | Renal Department GOSH |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Hull and East Yorkshire Hospitals NHS Trust |
| Department | Renal Hull and East Yorkshire |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | King's College Hospital NHS Foundation Trust (NCH) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Leicester General Hospital |
| Department | Renal Unit |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Manchester University NHS Foundation Trust |
| Department | Renal Care |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Department | Renal NHSGGC |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Queen Alexandra Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Royal Free London NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Salford Royal NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Department | Renal Unit Sheffield Teaching Hospitals |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GAMBIT consortium |
| Organisation | St George's Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Collaborator Contribution | Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance |
| Impact | Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested |
| Start Year | 2010 |
| Description | GP-TCM |
| Organisation | University of Mons |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | I advised the research design and drafted part of the project and provided critical review and revision. |
| Collaborator Contribution | Everyone brings in their perspectives and literature study outcomes in terms of integrated toxicological approaches to herbal medicines. I provided my perspectives as the PI of the GP-TCM project and as a nephrologist. |
| Impact | his a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary |
| Start Year | 2007 |
| Description | Harvard University |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | We have built a research collaboration on biomarkers in transplantation with Professor Terry Strom, by giving him access to patients and testing his samples in the kidney transplant unit. We have jointly written grant awards (L. Barber and S. Longi) and we have jointly funded a joint postdoctoral researcher to look at tissue stress factors in transplantation. In addition, we have set up teaching sessions to introduce research opportunities from Harvard University and we have set up a major international symposium (GMEC Genetics Symposium, November 2009) which featured his work. |
| Collaborator Contribution | We have access to confidential information and primer sequences that define potential biomarkers currently under investigation in our Centre as a result. It has facilitated recruitment of a new Professor to the MRC Centre from the USA. |
| Impact | 1. Organising GMEC Genetics Symposium (2009) 2. Organising workshops 3. Putting in two grant applications 4. Partnership with Quest (negotiation stage) |
| Start Year | 2007 |
| Description | Immune Tolerance Network |
| Organisation | Immune Tolerance Network |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Myself and my research team are participating as mechanistic investigators in 2 US multi-centre clinical trials of immunosuppression withdrawal in liver transplantation: iWITH (paediatric liver transplantation) and OPTIMAL (adult liver transplantation). Our contributions are: 1) scientific input into the design of the experimental plan of the studies; 2) performance of high-throughput gene expression analyses on biological specimens collected as part of the trials; 3) multi-parameter bioinformatic analysis of clinical and molecular data; 4) contribution to dissemination of the results. |
| Collaborator Contribution | The Immune Tolerance Network is providing biological specimens and funds to conduct the transcriptional studies, as well as the associated meta-data to perform the multi-parameter analysis. |
| Impact | No outputs yet. |
| Start Year | 2012 |
| Description | Indices of Tolerance |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Indices of Tolerance |
| Organisation | Immune Tolerance Network |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Indices of Tolerance |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Indices of Tolerance |
| Organisation | Milenia Biotec GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Indices of Tolerance |
| Organisation | University Libre Bruxelles (Université Libre de Bruxelles ULB) |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Indices of Tolerance |
| Organisation | University of Nantes |
| Country | France |
| Sector | Academic/University |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Indices of Tolerance |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients |
| Collaborator Contribution | Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc .... |
| Impact | JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu. |
| Description | Interdisciplinary Transplant Research Group |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation |
| Collaborator Contribution | Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol. |
| Impact | Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology. |
| Start Year | 2013 |
| Description | Interdisciplinary Transplant Research Group |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation |
| Collaborator Contribution | Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol. |
| Impact | Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology. |
| Start Year | 2013 |
| Description | Interdisciplinary Transplant Research Group |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation |
| Collaborator Contribution | Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol. |
| Impact | Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology. |
| Start Year | 2013 |
| Description | Ipierian |
| Organisation | Bristol-Myers Squibb |
| Department | iPerian |
| Country | United States |
| Sector | Private |
| PI Contribution | Tested the biological activity of antibody against the classical pathway of complement in an animal model. |
| Collaborator Contribution | Provided the antibody and funding. |
| Impact | showed the antibody (against human complement) was non functional in a rat model system. |
| Start Year | 2013 |
| Description | Islet research group Dresden |
| Organisation | University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Sharing of human islet resources; collaborative grant application for trial of implantable device |
| Collaborator Contribution | Our team provide human islets for research and we are about to start a King's based Diabetes UK funded study of implanting minimal islet mass in an immune isolating device in adults with type 1 diabetes as a pilot trial. £ 79020 has been awarded from Diabetes UK. |
| Impact | 1st successful grant application |
| Start Year | 2014 |
| Description | Jean-Paul Decuypere ERA-EDTA fellowship |
| Organisation | Catholic University of Louvain |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | ongoing scientific collaboration, support by offering space ad facilities available for the research to be carried out and shared authorship of any publications that may arise form this collaboration; enabled fellow to obtain an ERA-EDTA fellowship. |
| Collaborator Contribution | Bring expertise in autophagy tot he Centre and the ongoing research programme on Complement research. |
| Impact | ERA-EDTA fellowship |
| Start Year | 2014 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Addenbrooke's Hospital |
| Department | Liver Transplant Team |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | August Pi i Sunyer Biomedical Research Institute |
| Department | Hospital Clinic of Barcelona |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Brussels Saint-Luc University Hospital (UCL) |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Charité Campus Virchow - Hospital |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Hannover Medical School |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Queen Elizabeth Hospital Birmingham |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | Royal Free Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | University Hospitals Leuven |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | LIFT multi-centre clinical trial |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Myself and my research team we are coordinating a multi-centre clinical trial of biomarker-guided immunosuppression withdrawal in liver transplantation (LIFT trial, NIHR-EME funded) |
| Collaborator Contribution | Our partners contribute to the performance of the clinical trial by enrolling patients, following the clinical trial protocol and providing biological specimens and clinical data. |
| Impact | No outcomes yet |
| Start Year | 2015 |
| Description | Lecture tour of China |
| Organisation | Xi'an Jiaotong University |
| Department | School of Medicine Xi'an Jiaotong |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Lecturing to establish collaborations in research |
| Collaborator Contribution | will be mutual cooperation on various projects |
| Impact | None yet |
| Start Year | 2013 |
| Description | Lecture tour of China 2 |
| Organisation | Zhejiang University |
| Department | Institute of Respiratory Medicine |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Hoping to gain collaborative partners in research |
| Collaborator Contribution | Mutual cooperation in research projects |
| Impact | none yet |
| Start Year | 2013 |
| Description | Lombardi-Mullen |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | regulatory T cell expertise and models of skin transplantation |
| Collaborator Contribution | expertise in full body imaging |
| Impact | 2 publications already in pub med and 3 more in preparation |
| Start Year | 2008 |
| Description | Lombardi-Nestle |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | regulatory T cell expertise and knowledge in the mechanisms of tolerance |
| Collaborator Contribution | establishing in vivo model of human skin transplantation |
| Impact | See publications - PubMed ID 22937164 & J.Exp.Med.209(5) 935-945; Ali et al. Plos ONE (In Press) |
| Start Year | 2008 |
| Description | MABSOT Trial |
| Organisation | Opsona Therapeutics |
| Country | Ireland |
| Sector | Private |
| PI Contribution | Co-Chief investigator for the clinical trial. PI on work packages in animal, biomarker and Serum Amyloid A studies to support the trial. |
| Collaborator Contribution | Provided the therapeutic agent, anti-TLR2 antibody. They also provided the contract work for analysis of biomarkers (with Almac). |
| Impact | Drug manufacture. Completion of Phase 1 study in healthy volunteers. Identification of several potential biomarkers for ischaemia reperfusion injury of transplanted kidney. Clinical Trial recruitment started. |
| Start Year | 2011 |
| Description | MRC Centre for Transplantation |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Team has become emerged within the centre |
| Collaborator Contribution | Increased collaboration with Richard Smith, Steve Sacks, Gio Lombardi and Maria Hernandez-Fuentes. All have had significant intellectual input into the work |
| Impact | Being within the MRC Centre, within King's College London, within Guy's Hospital has significantly contributed to success in applications to British Heart Foundation, Kidney Research UK and commercial organisations for research funding. |
| Start Year | 2009 |
| Description | Mark Thursz |
| Organisation | Imperial College Healthcare NHS Trust |
| Department | Liver Department |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | supply of mice. delivery of a seminar, plus intellectual input into the |
| Collaborator Contribution | began a new line of enquiry in a model of liver fibrosis, looking at the contribution of coagulation proteins |
| Impact | Abstract at international meeting 2012 |
| Start Year | 2010 |
| Description | Mirococept collaboration with Cambridge University |
| Organisation | University of Cambridge |
| Department | Veterinary School |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Supplied Mirococept and other reagents and collaborated in experiments. |
| Collaborator Contribution | Providing laboratory facilities and Factor I |
| Impact | Supportive data for clinical use of Mirococept in novel indications. |
| Start Year | 2013 |
| Description | NIH Xenotransplantation at Pittsburgh |
| Organisation | University of Pittsburgh |
| Department | Thomas E Starzl Transplantation Institute |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaborator on NIH-funded Xenotransplantation programme. Latterly, advisor to renewed prgramme |
| Collaborator Contribution | PhD student to work/train in my lab. Collaboration to supply membrane tethered hirulog (thrombalexin) 2013 |
| Impact | Multiple papers, reported elsewhere - 1st author Lin CC |
| Start Year | 2006 |
| Description | Novartis |
| Organisation | Novartis |
| Department | Transplantation & Immunology |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | Two way sharing of data and techniques - including a trip to Basel in August 2011 to visit Novartis Global Research and to give a talk |
| Collaborator Contribution | Financial assistance, technical help |
| Impact | Paper in preparation. |
| Start Year | 2011 |
| Description | OuTSMART investigators |
| Organisation | Manchester University NHS Foundation Trust |
| Department | Renal Care |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | All are co-applicants on OuTSMART grant |
| Collaborator Contribution | Co-PIs at recruitment site |
| Impact | None yet, except OuTSMART trial initiated and recruitment started. |